TapImmune's technology has broad applications in developing therapeutic and preventative vaccines.
Our strategy is to build a patented proprietary product pipeline and capitalize on the breadth of the TAP technology through collaborative partnerships and license agreements.
To achieve success, TapImmune's strategy for growth is to:
- Conduct preclinical vaccine programs and move successes through to human trials
- Discover, acquire and develop technologies that modulate antigen presentation
- Commercialize proprietary products through corporate alliances
- Develop business partnerships that enhance the efficacy of other immunotherapeutic and vaccine products